NCT06684041已完成1 期
Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Study of Multiple Doses of HRS-5965 Capsules in Healthy Subjects and a Phase I Clinical Trial of the Effect of HRS-5965 on QT Interval in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- Incidence of subjects with adverse events (AEs)
研究概览
简要总结
This was a randomized, double-blind, single-dose, placebo-controlled phase I clinical trial. This study plans to conduct three dose groups of dose 1, dose 2, and dose 3. A total of 32 healthy subjects were planned to be enrolled.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Voluntarily sign the informed consent form before any activities related to this trial, be able to understand the procedures and methods of this trial, and be willing to complete this trial in strict accordance with the clinical trial protocol.
- •Aged between 18 and 45 years old (based on the time of signing the informed consent form), both males and females are eligible.
- •The body weight of males ≥ 50 kg, and that of females ≥ 45 kg, and body mass index (BMI): 19 - 26 kg/m².
- •During the screening period, there are no abnormalities in physical examination, vital signs, twelve - lead electrocardiogram, frontal and lateral chest radiographs, abdominal ultrasound, and laboratory tests, or those with minor abnormalities but judged by the investigator to be of no clinical significance.
- •During the screening period, human immunodeficiency virus antibody (HIV - Ab), treponema pallidum antibody, hepatitis B surface antigen (HBsAg), and hepatitis C virus antibody (HCV - Ab) are all negative.
- •Complete the vaccination of Neisseria meningitidis and Streptococcus pneumoniae vaccines 2 weeks before the first administration of HRS - 5965.
排除标准
- •The researcher has determined that there may be diseases or medical conditions that affect the absorption, distribution, metabolism and excretion of drugs or reduce compliance.
- •According to the judgment of the researcher, any physiological or psychological disease or condition that may increase the risk of the test, affect the subject's compliance with the protocol, or affect the subject's completion of the test.
- •Those with a previous history of Neisseria meningitidis infection, or those whose first - degree relatives have a history of Neisseria meningitidis infection.
- •Those with definite evidence of infection within 2 weeks before screening (positive etiological examination, or having received systemic antibiotic treatment), or those who have had a body temperature exceeding 38 °C.
- •Subjects with abnormal serum electrolytes (hypokalemia, hypomagnesemia, hypocalcemia).
- •Subjects with a history of convulsive disorders, long QT syndrome (including family history), syncope while swimming or any other type of syncope or history of loss of consciousness.
- •Subjects with a previous history of heart disease, such as hypertension, atherosclerosis, heart failure, bradycardia or stroke, or those using a pacemaker.
- •Those with a serum creatinine level exceeding the upper limit of the normal value, or those whose level does not exceed the upper limit but are judged by the investigator to be at risk of renal function impairment.
- •Those with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) exceeding the upper limit of normal value (ULN), or with total bilirubin exceeding 1.5 times the ULN.
研究组 & 干预措施
Dose 1
Experimental
干预措施: HRS-5965 capsule (Drug)
Dose 1
Experimental
干预措施: HRS-5965 capsule placebo (Drug)
Dose 2
Experimental
干预措施: HRS-5965 capsule (Drug)
Dose 2
Experimental
干预措施: HRS-5965 capsule placebo (Drug)
Dose 3
Experimental
干预措施: HRS-5965 capsule (Drug)
Dose 3
Experimental
干预措施: HRS-5965 capsule placebo (Drug)
结局指标
主要结局
Incidence of subjects with adverse events (AEs)
时间窗: Baseline up to seven days after the last dosing.
Incidence of AEs, including any abnormal findings in vital signs, and/or physical examination and/or clinical laboratory assessments and/or 12-lead ECG evaluation.
QTcF: Baseline and placebo-adjusted QTcF after oral HRS-5965 capsules
时间窗: Baseline up to 24 hours after dosing.
次要结局
- Area under the plasma concentration-time curve from time zero to the time of last quantifiable analyte concentration (AUC0-t) for HRS-5965(Baseline up to seven days after the last dosing.)
- Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC0-∞) for HRS-5965(Baseline up to seven days after the last dosing.)
- Maximum plasma concentration (Cmax) for HRS-5965(Baseline up to seven days after the last dosing.)
- Time to reach maximum plasma concentration (Tmax) for HRS-5965(Baseline up to seven days after the last dosing.)
- Terminal half-life (t1/2) for HRS-5965(Baseline up to seven days after the last dosing.)
- Apparent clearance (CL/F) of HRS-5965 for administration subcutaneously(Baseline up to seven days after the last dosing.)
- Apparent volume of distribution (V/F) of HRS-5965 for administration subcutaneously(Baseline up to seven days after the last dosing.)
- Complement system alternative pathway (AP) inhibition efficiency(Baseline up to seven days after the last dosing.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-7249 Injection in Healthy SubjectsHyperlipidemiaNCT06541457Fujian Shengdi Pharmaceutical Co., Ltd.48
已完成
1 期
Safety, Tolerability and Pharmacokinetics of CDD-2101 in Health VolunteersConstipation - FunctionalNCT06570668Centre for Chinese Herbal Medicine Drug Development Limited20
已完成
1 期
Safety Study of Intravenous Ertapenem in Combination With Zidebactam (WCK 6777)Bacterial InfectionNCT05645757National Institute of Allergy and Infectious Diseases (NIAID)54
已完成
1 期
Single Dose of PF-06835919 Escalation Study in Healthy Adult SubjectsNon-alcoholic Fatty Liver DiseaseNCT02974374Pfizer16
已完成
1 期
Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly SubjectsAlzheimer's DiseaseNCT01467726Alfasigma S.p.A.40